A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosisHoward Trachtman, Flavio Vincenti, James B. Streisand et al.|Kidney International|2011Cited by 258